FutureMeds LTD

FutureMeds LTD, based in the UK, specializes in delivering clinical trial solutions focusing on decentralized clinical trials, enhancing patient engagement and improving trial efficiency. Founded in 2019 in Wirral, UK, FutureMeds LTD focuses on providing clinical trial services. The company was established by experienced industry professionals. FutureMeds has executed 1 deal, with the most recent deal taking place on July, 2025, when Phoenix Equity Partners invested in the firm.

FutureMeds specializes in offering a comprehensive suite of services tailored for the clinical trial industry, particularly in decentralized clinical trials (DCTs). Their core offerings include patient-centric engagement strategies that facilitate recruitment and retention for clinical studies. Utilizing a strong site network and experienced principal investigators (PIs), FutureMeds enhances the efficiency and speed of clinical trials while collecting high-quality data. Their services span various therapy areas, including cardiovascular, immunology, metabolic disorders, and oncology, and support operations in 18 European countries such as the UK, Poland, Spain, and Germany.

FutureMeds generates revenue primarily through B2B partnerships with sponsors and contract research organizations (CROs) looking to conduct clinical trials. Their transactional structure involves service agreements for patient recruitment and trial management services, where clients pay for specific services like site management and data collection based on successful trial participant enrollment and retention. The company’s established DCT solutions and reputation for delivering results further solidify their partnerships with healthcare professionals and research entities. In July 2025, FutureMeds LTD secured investment from Phoenix Equity Partners, the specifics of which have not been disclosed.

This funding will enable the company to expand its geographical presence and enhance its expertise across a wider range of therapeutic areas. FutureMeds is focused on launching new products designed to improve clinical trial operations, alongside plans for entering additional European markets to broaden its reach.